Which ICU patients need stress ulcer prophylaxis?
Mariam Saeed1, Stephanie Bass2, Neal F Chaisson3
1Respiratory Institute, Cleveland Clinic, Cleveland, OH saeedm@ccf.org.
Critically ill patients often receive stress ulcer prophylaxis. However, acid-suppressing drugs may increase risks of hospital-acquired pneumonia and Clostridioides difficile infection, prompting a review of current practices.
Area of Science:
- Critical care medicine
- Gastroenterology
- Pharmacology
Background:
- Critically ill patients face a high risk of upper gastrointestinal stress ulcers.
- Stress ulcer bleeding is linked to longer intensive care unit (ICU) stays and increased mortality.
- Stress ulcer prophylaxis is standard in ICUs, but concerns about associated infections are rising.
Purpose of the Study:
- To review the controversies surrounding stress ulcer prophylaxis in critically ill patients.
- To provide evidence-based guidance on the appropriate use of stress ulcer prophylaxis.
Main Methods:
- Literature review of studies on stress ulcer prophylaxis in critically ill patients.
- Analysis of the risks and benefits of acid-suppression drugs for prophylaxis.
- Evaluation of evidence linking prophylaxis to nosocomial infections.
Main Results:
- Acid-suppression medications, commonly used for prophylaxis, are associated with increased risks of hospital-acquired pneumonia and Clostridioides difficile infections.
- The benefits of routine stress ulcer prophylaxis in all critically ill patients are debated.
- Risk stratification may be necessary to identify patients who truly benefit from prophylaxis.
Conclusions:
- The use of stress ulcer prophylaxis in critically ill patients requires careful consideration of potential harms, particularly infectious complications.
- Guidelines should emphasize selective use of prophylaxis based on individual patient risk factors.
- Further research is needed to optimize prophylaxis strategies and minimize adverse events.
More Related Videos
Related Concept Videos
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...


